Objective:To systematically evaluate the efficacy and safety of ixazomib in patients with relapsed or refractory multiple myeloma (RRMM) in the real world.Methods:Relevant databases at home and abroad were searched (up to April 2022), and the literature on real-world studies of ixazomib in the treatment of RRMM was collected. The quality of the literature was evaluated with the methodological index for non-randomized studies (MINORS) scale. Data such as the effectiveness rate and incidence of adverse events in RRMM patients treated with ixazomib were extracted. The effectiveness indicators included the overall response rate (ORR), very good partial response or better (≥VGPR) rate and median progression-free survival (PFS). The safety indicators included the incidence of adverse events (AEs) and the rate of treatment termination due to AEs, etc. Stata 13.0 software was used for meta-analysis of single proportions, and the occurrence of major adverse events was analyzed by descriptive statistics.Results:A total of 12 studies were entered, including 1 006 patients. The quality evaluation results showed that all of the 12 studies were with high quality. The meta-analysis of single proportions showed that ORR of ixazomib in the treatment of RRMM was 65%[95% confidence interval ( CI): 58%-72%], ≥VGPR rate was 32% (95% CI: 25%-38%), the median PFS was 21.73 (95% CI: 14.37-29.08) months, the incidence of ≥ grade 3 AEs was 39% (95% CI: 24%-55%), and the incidence of treatment termination due to AEs was 6% (95% CI: 3%-10%). AEs with an incidence of ≥10% included neutropenia, thrombocytopenia, infection, anemia, diarrhea, fatigue, peripheral neuropathy, rashes, and bone pain. Conclusion:In the real world, the efficacy of ixazomib in the treatment of RRMM is lower than that in clinical trials, but the safety is similar.

Objective:To systematically evaluate the efficacy and safety of ixazomib in patients with relapsed or refractory multiple myeloma (RRMM) in the real world.Methods:Relevant databases at home and abroad were searched (up to April 2022), and the literature on real-world studies of ixazomib in the treatment of RRMM was collected. The quality of the literature was evaluated with the methodological index for non-randomized studies (MINORS) scale. Data such as the effectiveness rate and incidence of adverse events in RRMM patients treated with ixazomib were extracted. The effectiveness indicators included the overall response rate (ORR), very good partial response or better (≥VGPR) rate and median progression-free survival (PFS). The safety indicators included the incidence of adverse events (AEs) and the rate of treatment termination due to AEs, etc. Stata 13.0 software was used for meta-analysis of single proportions, and the occurrence of major adverse events was analyzed by descriptive statistics.Results:A total of 12 studies were entered, including 1 006 patients. The quality evaluation results showed that all of the 12 studies were with high quality. The meta-analysis of single proportions showed that ORR of ixazomib in the treatment of RRMM was 65%[95% confidence interval ( CI): 58%-72%], ≥VGPR rate was 32% (95% CI: 25%-38%), the median PFS was 21.73 (95% CI: 14.37-29.08) months, the incidence of ≥ grade 3 AEs was 39% (95% CI: 24%-55%), and the incidence of treatment termination due to AEs was 6% (95% CI: 3%-10%). AEs with an incidence of ≥10% included neutropenia, thrombocytopenia, infection, anemia, diarrhea, fatigue, peripheral neuropathy, rashes, and bone pain. Conclusion:In the real world, the efficacy of ixazomib in the treatment of RRMM is lower than that in clinical trials, but the safety is similar.

Objective To obtain sufficient recombinant VP2 protein of human Bocavirus and establish it's seroepidemiology assying methord.Methord The capsid protein VP2 DNA genes of HBoV1 and 2 were optimized in accordance with the usage of the favorite codons in E.coil so as to enhance its protein expression in prokaryotic expressing system.The protein was purified by Ni-NTA column,and its antigenicity was determined by Western Blot.Then establish ELISA to detect the specific anti-VP2 IgG antibodies against HBoV1 and 2 in healthy children aged 3 - 6 years in Nanjing,China.Results The recombinant protein 6 × His-VP2 was produced in a larger quantity at 25℃ induced by IPTG (lmmol/L) over night and purified by Ni-NTA column.Seropositive rates of HBoV1and 2 were 62.2％ and 55.5％ and their mixed seropositivity was 37％.Conclusion The optimizing expression of the capsid protein VP2 from human Bocavirus constructed successfully and get a high yield under certain conditions.The established ELISA could be used to further analyze seroepidemiology of HBoV in china.

OBJECTIVEStudy on the flavonoids from the air part of Eupatorium lindleyanum.

METHODAlcohol percolation, silica gel column chromatography and re-crystallization et al.

RESULTJaceosidin, kaempferol, quceritin, astragalin, trifolin and hypersoide were isolated from E. lindleyanum. Their structures were elucidated on the basis of spectral evidence.

CONCLUSIONJaceosidin, kaempferol, quceritin, astragalin and trifolin were isolated from E. lindleyanum for the first time.

Eupatorium ; chemistry ; Flavonoids ; chemistry ; isolation & purification ; Kaempferols ; chemistry ; isolation & purification ; Plant Components, Aerial ; chemistry ; Plants, Medicinal ; chemistry ; Quercetin ; chemistry ; isolation & purification